▸ 14 Sep 2026, 16:41 Application for quotation of securities - TLX Securities Administration
▸ 14 Sep 2026, 08:21 FDA Approves Telix Brain Cancer Imaging Drug Pixclara Company Update
▸ 2 Sep 2026, 08:16 Telix Completes Enrollment in Phase 3 BiPASS Study Company Update
▸ 1 Sep 2026, 08:18 Telix Appoints David Gill as Chair Company Administration
▸ 20 Aug 2026, 08:42 Telix HY26 Results Presentation Financial Results
▸ 20 Aug 2026, 08:41 Telix HY26 Results Announcement Financial Results
▸ 20 Aug 2026, 08:40 Telix HY26 Appendix 4D and Interim Report Financial Results
▸ 31 Jul 2026, 08:30 Telix H1 2026 Results - Investor Webcast Notification Presentations
▸ 24 Jul 2026, 08:21 Change in substantial holding Substantial Holders
▸ 21 Jul 2026, 08:26 Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress Company Update
▸ 10 Jul 2026, 08:24 Notification of cessation of securities - TLX Securities Administration
▸ 10 Jul 2026, 08:24 Notification regarding unquoted securities - TLX Securities Administration
▸ 10 Jul 2026, 08:24 Application for quotation of securities - TLX Securities Administration
▸ 8 Jul 2026, 17:49 Change in substantial holding Substantial Holders
▸ 3 Jul 2026, 13:36 Ceasing to be a substantial holder Substantial Holders
▸ 2 Jul 2026, 10:07 FDA Alignment to Advance ProstACT Global Phase 3 Trial Company Update
▸ 1 Jul 2026, 12:38 Change in substantial holding Substantial Holders
▸ 1 Jul 2026, 08:17 Change in substantial holding Substantial Holders
▸ 30 Jun 2026, 17:24 Becoming a substantial holder Substantial Holders
▸ 25 Jun 2026, 08:16 Becoming a substantial holder Substantial Holders
▸ 23 Jun 2026, 17:32 Ceasing to be a substantial holder Substantial Holders
▸ 17 Jun 2026, 08:24 Appendix 3Y Change in Director Interest D Gill Director Interests
▸ 9 Jun 2026, 08:13 Change in substantial holding Substantial Holders
▸ 1 Jun 2026, 15:26 Notification regarding unquoted securities - TLX Securities Administration
▸ 1 Jun 2026, 15:20 Appendix 3Y Change in Director Interest - C Behrenbruch Director Interests
▸ 1 Jun 2026, 15:16 Appendix 3Y Change in Director Interest - M McDonald Director Interests
▸ 1 Jun 2026, 15:15 Appendix 3Y Change in Director Interest - W Jellison Director Interests
▸ 1 Jun 2026, 15:12 Appendix 3Y Change in Director Interest - Maria Rivas Director Interests
▸ 1 Jun 2026, 15:11 Appendix 3Y Change in Director Interest - David Gill Director Interests
▸ 26 May 2026, 16:50 Becoming a substantial holder Substantial Holders
▸ 21 May 2026, 13:00 Results of Annual General Meeting Meetings & Governance
▸ 21 May 2026, 09:39 Telix Annual General Meeting Presentation Presentations
▸ 21 May 2026, 09:38 Telix Annual General Meeting Chairman and CEO Addresses Letters & Addresses
▸ 14 May 2026, 09:27 App 3X Initial Director Interests - W Jellison Director Interests
▸ 14 May 2026, 09:21 App 3X Initial Director Interests - M Rivas Director Interests
▸ 14 May 2026, 09:20 App 3X Initial Director Interests - D Gill Director Interests
▸ 11 May 2026, 18:01 Change in substantial holding Substantial Holders
▸ 8 May 2026, 10:14 Cleansing Notice Securities Administration
▸ 8 May 2026, 09:10 Application for quotation of securities - TLX Securities Administration
▸ 8 May 2026, 09:04 Notification regarding unquoted securities - TLX Securities Administration
▸ 6 May 2026, 16:28 Ceasing to be a substantial holder from CGF Substantial Holders
▸ 30 Apr 2026, 08:14 Appendix 3Y Change in Director Interests - C Behrenbruch Director Interests
▸ 29 Apr 2026, 17:56 Pending Release of Shares from Voluntary Escrow Securities Administration
▸ 29 Apr 2026, 08:18 Change in substantial holding Substantial Holders
▸ 28 Apr 2026, 08:20 Webinar - A Next-Gen Portfolio Approach to PSMA Therapy Presentations
▸ 23 Apr 2026, 11:05 Notification regarding unquoted securities - TLX Securities Administration
▸ 23 Apr 2026, 09:41 Telix Announces Settlement of US$600M Convertible Bonds Company Administration
▸ 21 Apr 2026, 08:17 Telix Notice of AGM, Proxy Form and Online Guide Meetings & Governance
▸ 20 Apr 2026, 16:47 Convertible Bond Cleansing Notice Securities Administration
▸ 17 Apr 2026, 16:26 Becoming a substantial holder from CGF Substantial Holders
▸ 17 Apr 2026, 08:24 Change in substantial holding Substantial Holders
▸ 16 Apr 2026, 16:55 Notification regarding unquoted securities - TLX Securities Administration
▸ 16 Apr 2026, 16:51 Notification of cessation of securities - TLX Securities Administration
▸ 15 Apr 2026, 09:34 Appendix 3B Securities Administration
▸ 15 Apr 2026, 08:14 Telix Successfully Prices Upsized US$600M Convertible Bonds Capital Raising
▸ 14 Apr 2026, 17:08 Telix Investor Presentation April 2026 Presentations
▸ 14 Apr 2026, 16:54 Telix Refinances Convertible Bonds Capital Raising
▸ 13 Apr 2026, 08:27 Telix and Regeneron Announce Radiopharma Collaboration Company Update
▸ 10 Apr 2026, 17:01 Ceasing to be a substantial holder Substantial Holders
▸ 10 Apr 2026, 08:26 FDA Accepts NDA for TLX101-Px (Pixclara) Company Update
▸ 9 Apr 2026, 16:12 Becoming a substantial holder Substantial Holders
▸ 9 Apr 2026, 10:00 Notification regarding unquoted securities - TLX Securities Administration
▸ 9 Apr 2026, 09:57 Application for quotation of securities - TLX Securities Administration
▸ 9 Apr 2026, 08:23 Telix Strengthens Board with Further Director Appointments Company Administration
▸ 7 Apr 2026, 16:35 Ceasing to be a substantial holder from CGF Substantial Holders
▸ 7 Apr 2026, 08:28 Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement Periodic Reports
▸ 2 Apr 2026, 16:18 Ceasing to be a substantial holder Substantial Holders
▸ 2 Apr 2026, 09:52 Telix Appoints David Gill as Non-Executive Director Company Administration
▸ 20 Mar 2026, 15:15 Change in substantial holding Substantial Holders
▸ 20 Mar 2026, 08:23 Notification regarding unquoted securities - TLX Securities Administration
▸ 18 Mar 2026, 08:24 Appendix 3Y Change in Director Interests - C Behrenbruch Director Interests
▸ 18 Mar 2026, 08:24 Notification of cessation of securities - TLX Securities Administration
▸ 17 Mar 2026, 17:32 Becoming a substantial holder Substantial Holders
▸ 16 Mar 2026, 08:19 Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging Company Update
▸ 12 Mar 2026, 16:23 Becoming a substantial holder from CGF Substantial Holders
▸ 12 Mar 2026, 08:30 Notification of cessation of securities - TLX Securities Administration
▸ 12 Mar 2026, 08:30 Application for quotation of securities - TLX Securities Administration
▸ 10 Mar 2026, 08:24 ProstACT Global Phase 3 (Part 1) Results Presentation Presentations
▸ 10 Mar 2026, 08:24 ProstACT Global Phase 3 (Part 1) Achieves Primary Objectives Company Update
▸ 9 Mar 2026, 08:19 Pending Release of Shares from Voluntary Escrow Securities Administration
▸ 6 Mar 2026, 19:30 Change in substantial holding Substantial Holders
▸ 5 Mar 2026, 08:56 Application for quotation of securities - TLX Securities Administration
▸ 20 Feb 2026, 08:54 Appendix 4G and 2025 Corporate Governance Statement Company Administration
▸ 20 Feb 2026, 08:53 2025 Full Year Results Presentation Financial Results
▸ 20 Feb 2026, 08:53 2025 Full Year Results Announcement Financial Results
▸ 20 Feb 2026, 08:52 Appendix 4E and 2025 Annual Report Financial Results
▸ 20 Feb 2026, 08:18 Change in substantial holding Substantial Holders
▸ 18 Feb 2026, 08:16 Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging Company Update
▸ 9 Feb 2026, 08:11 Change in substantial holding Substantial Holders
▸ 4 Feb 2026, 08:27 App 3Z Final Director Interests - T Olson Director Interests
▸ 4 Feb 2026, 08:27 Telix Full Year Results 2025 Investor Webcast Notification Presentations
▸ 3 Feb 2026, 09:07 Chair Resignation, Dr Mark Nelson appointed Interim Chair Company Administration
▸ 2 Feb 2026, 20:20 Change in substantial holding Substantial Holders
▸ 27 Jan 2026, 08:11 Becoming a substantial holder Substantial Holders
▸ 23 Jan 2026, 16:08 Ceasing to be a substantial holder from CGF Substantial Holders
▸ 23 Jan 2026, 08:25 Pending Release of Shares from Voluntary Escrow Securities Administration
▸ 23 Jan 2026, 08:24 Ceasing to be a substantial holder Substantial Holders
▸ 20 Jan 2026, 17:07 Telix Achieves FY25 Guidance - US$804M, Q4 Growth Company Update
▸ 20 Jan 2026, 08:25 Chinese NMPA Accepts New Drug Application for Illuccix Company Update
▸ 14 Jan 2026, 08:35 Appendix 2A updated Securities Administration